Discounted Cash Flow
Mereo Biopharma Group Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | — | $-38.8m | $-32.2m | — | $-0.56 |
| 2018 | — | $-32.0m (17.4%) | $-23.2m (28.0%) | — | $-0.45 (19.6%) |
| 2019 | — | $-34.8m (-8.8%) | $-47.5m (-105.0%) | — | $-0.39 (13.3%) |
| 2020 | — | $-163.6m (-369.6%) | $-29.9m (37.0%) | — | $-0.48 (-23.1%) |
| 2021 | $36.5m | $12.7m (107.8%) | $-5.9m (80.4%) | 34.9% | $0.02 (104.2%) |
| 2022 | $0 (-100.0%) | $-34.2m (-368.7%) | $-39.5m (-572.5%) | — | $-0.06 (-400.0%) |
| 2023 | $10.0m | $-29.5m (13.8%) | $-21.1m (46.6%) | -294.7% | $-0.04 (33.3%) |
| 2024 | $1.7m (-83.3%) | $-43.3m (-46.8%) | $-33.5m (-58.7%) | -2588.5% (-778.5%) | $-0.06 (-50.0%) |
| 2025 | $1.9m (14.8%) | $-41.9m (3.2%) | $-31.0m (7.6%) | -2183.4% (15.6%) | $-0.05 (16.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.